These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37685551)

  • 1. Clinical Utility of Pre-Therapeutic [18F]FDG PET/CT Imaging for Predicting Outcomes in Breast Cancer.
    Najid S; Seban RD; Champion L; De Moura A; Sebbag C; Salaün H; Cabel L; Bonneau C
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
    Seban RD; Arnaud E; Loirat D; Cabel L; Cottu P; Djerroudi L; Hescot S; Loap P; Bonneau C; Bidard FC; Huchet V; Jehanno N; Berenbaum A; Champion L; Buvat I
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4024-4035. PubMed ID: 37606858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer.
    Seban RD; Rouzier R; Latouche A; Deleval N; Guinebretiere JM; Buvat I; Bidard FC; Champion L
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3560-3570. PubMed ID: 33774685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
    Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer.
    Seban RD; Champion L; De Moura A; Lerebours F; Loirat D; Pierga JY; Djerroudi L; Genevee T; Huchet V; Jehanno N; Bidard FC; Buvat I
    Eur J Nucl Med Mol Imaging; 2024 Oct; ():. PubMed ID: 39373900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis.
    Wu Y; Li Y; Chen B; Zhang Y; Xing W; Guo B; Wang W
    Oncologist; 2024 Dec; 29(12):e1646-e1655. PubMed ID: 39045652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy.
    Grambow-Velilla J; Seban RD; Chouahnia K; Assié JB; Champion L; Girard N; Bonardel G; Matton L; Soussan M; Chouaïd C; Duchemann B
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190152
    [No Abstract]   [Full Text] [Related]  

  • 9. The usefulness of the total metabolic tumor volume for predicting the postoperative recurrence of thoracic esophageal squamous cell carcinoma.
    Kaida H; Yasuda T; Shiraishi O; Kato H; Kimura Y; Hanaoka K; Yamada M; Matsukubo Y; Tsurusaki M; Kitajima K; Hattori S; Ishii K
    BMC Cancer; 2022 Nov; 22(1):1176. PubMed ID: 36376801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of baseline total metabolic tumour volume of
    Gong H; Li T; Li J; Tang L; Ding C
    EJNMMI Res; 2021 Jul; 11(1):64. PubMed ID: 34264417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volumetric parameters from [
    Langen Stokmo H; Aly M; Bowitz Lothe IM; Borja AJ; Mehdizadeh Seraj S; Ghorpade R; Miao X; Hjortland GO; Malinen E; Sorbye H; Werner TJ; Alavi A; Revheim ME
    J Neuroendocrinol; 2022 Jul; 34(7):e13170. PubMed ID: 35729738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
    Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
    Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer.
    Zer A; Domachevsky L; Rapson Y; Nidam M; Flex D; Allen AM; Stemmer SM; Groshar D; Bernstine H
    Eur Radiol; 2016 Sep; 26(9):3155-61. PubMed ID: 26685851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Seban RD; Mezquita L; Berenbaum A; Dercle L; Botticella A; Le Pechoux C; Caramella C; Deutsch E; Grimaldi S; Adam J; Ammari S; Planchard D; Leboulleux S; Besse B
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1147-1157. PubMed ID: 31754795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
    Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
    J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.